Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Net Income (2024 - 2025)

Xilio Therapeutics' Net Income history spans 2 years, with the latest figure at -$1.9 million for Q3 2025.

  • For Q3 2025, Net Income rose 86.93% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached -$43.8 million, changed N/A, while the annual FY2024 figure was -$60.6 million, 23.44% up from the prior year.
  • Net Income for Q3 2025 was -$1.9 million at Xilio Therapeutics, up from -$14.4 million in the prior quarter.
  • Across five years, Net Income topped out at -$1.9 million in Q3 2025 and bottomed at -$17.5 million in Q1 2024.